On the other hand, a promising strategy based on TCR isolation for neoepitope-specific TCR cloning and engineering of autologous CD8+ and CD4+ T-cells is being implemented in clinical trials that include patients with prostate cancer (NCT03970382). This evidence concerns the gene CD4 and Familial prostate cancer.